IMRABIOME – The Influence of Methotrexate on the RA microbiome

Principle Investigator:
Dr Rod Hughes

A study in people newly diagnosed with Rheumatoid Arthritis (RA). The research project aims to investigate what role the microbiome (bacterial community) of the body plays in RA, and is designed to help us determine whether the microbiome influences disease progression and response to standard treatment. We are aiming to recruit 10 participants between now and August 2019. This study requires 3 assessments: Baseline, 3-month follow-up and 6-month follow-up.

This study is sponsored by King’s College London and Guys and St Thomas’s Foundation NHS Trust and funded by Arthritis Research UK.

GCA Consortium – Clinical and immunogenetic characterization of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)

Principle Investigator:
Dr Rod Hughes

A genetic study to find out more about the causes of GCA (sometimes called temporal arteritis) and PMR which will hopefully lead to the development of better treatments with fewer side effects than the steroid treatment that is currently standard. Participants must have GCA (with or without PMR). There is no limit to recruitment numbers nor a fixed end-date for this retrospective study.

This study is sponsored by the University of Leeds and funded by National Institute for Health Research, the Wellcome Trust, the Mason Medical Research Foundation, The Leeds Teaching Hospitals Charitable Foundation, and the Biomedical Health Research Centre at the University of Leeds.

BSRBR-RA - British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (RA) – Are new treatments for RA harmful to long term health?

Joint Principal Investigators:
Dr Rod Hughes, Dr Fazel Sheikh & Dr Gulam Patel

Biologic drugs for the treatment of RA have been available for two decades in the UK, with new drugs being approved each year. This study has been designed to collect data to ensure Biologics are safe and effective in the longer term. There is no limit to recruitment numbers nor a fixed end-date for this observational study.

This study is sponsored by the BSRBR and funded by Arthritis Research UK.

APIPPRA – Arthritis Prevention in the Pre-clinical Phase of Rheumatoid Arthritis with Abatacept.

Principle Investigator:
Dr Fazal Sheikh

To determine whether rheumatoid arthritis can be prevented if therapy is given to individuals at high risk of developing the disease, as defined by the presence of autoantibodies factor and together with joint pain. This is a 12-month therapy course with a biologic drug called Abatacept. This drug has been chosen as it has beneficial effects in established Rheumatoid Arthritis, a good safety profile and beneficial effects on reducing harmful immune responses.

This study is sponsored by Kings College, London.

The Genetics of Ankylosing Spondylitis

Principle Investigator:
Dr Rod Hughes

Ankylosing Spondylitis (AS) is a relatively common inflammatory disease mainly affecting the spine. It is known that AS can ‘run’ in families and that it has a strong genetic or inherited element. The goal is to identify as many of these genes as possible so that we can better understand the disease and develop better ways of diagnosing and treating it.

This study is sponsored by The Nuffield Orthopaedic Centre, Oxford and funded by The Wellcome Trust, National Ankylosing Spondylitis Society, Arthritis Research UK, National Institute for Health Research and Abbott Laboratories.